- Category: HIV Prevention
- Published on Wednesday, 01 August 2012 00:00
- Written by Gregory Fowler
Pre-exposure prophylaxis -- better known as PrEP -- for HIV prevention remains a controversial issue. At the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, Julio Montaner and Kenneth Mayer described new IAPAC PrEP guidelines and responded to concerns of a skeptical journalist.
[International Association of Physicians in AIDS Care press conference, 7/26/12]
The U.S. Food and Drug Administration approved Truvada PrEP (Gilead Sciences' tenofovir/emtricitabine combination pill) for prevention of sexual transmission of HIV on July 16, 2012.
Responding to the contention that PrEP is a toxic lifelong intervention, Montaner, from the British Columbia Centre for Excellence in HIV/AIDS, and Mayer, medical research director at the Fenway Institute in Boston, explained that PrEP was well-tolerated in studies to date (including iPrEx, Partners PrEP, and TDF2) and is intended as a time-limited "niche" intervention for selected individuals at high risk for infection.